首页> 外文期刊>Pharmacology & Pharmacy >Description of Prescribing Practices of Intrapleural Tissue Plasminogen Activator and Intrapleural DNase Administration at a Tertiary Academic Medical Center
【24h】

Description of Prescribing Practices of Intrapleural Tissue Plasminogen Activator and Intrapleural DNase Administration at a Tertiary Academic Medical Center

机译:三级学术医学中心的胸膜内组织纤溶酶原激活剂和胸膜内DNase处方操作的说明

获取原文
           

摘要

Objectives: To describe the prescribing practices, preparation and administration techniques of intrapleural (IP) tissue plasminogen activator (t-PA) and IP DNase in patients at a tertiary academic medical center. Methods: Adult patients receiving IP t-PA and IP DNase between January 1-December 31, 2012 were retrospectively evaluated. Patients were included if they received IP t-PA and/or IP DNase for a pleural infection and were excluded if they received IP t-PA or IP DNase for chest tube clearance. Results: A total of 197 doses of IP t-PA and IP DNase received amongst 30 patients were included. The mean age of the patients included was 62 years old with 50% of the patients being female. Of the 30 patients included, 18 patients (60%) received both IP t-PA and IP DNase and 12 patients (40%) received only IP t-PA. The median dose of IP t-PA received was 4 mg (IQR 2-10) and the median dose of IP DNase received was 5 mg (IQR 5-5). Systemic antibiotics were administered to 77% of patients prior to IP t-PA or IP DNase administration. Improved pleural effusion drainage was reported in 70% of patients. Increased pain in the chest cavity during administration of IP t-PA or IP DNase was reported in 7% of patients. Conclusion: The majority of patients at our institution received concomitant IP t-PA and IP DNase after systemic therapy for treatment of pleural infections had been attempted. Administration of IP t-PA and IP DNase demonstrated improved drainage of pleural infections with minimal harm to patients.
机译:目的:描述三级学术医学中心患者胸膜内(IP)组织纤溶酶原激活物(t-PA)和IP DNase的处方实践,制备和给药技术。方法:回顾性分析2012年1月1日至12月31日期间接受IP t-PA和IP DNase治疗的成年患者。如果接受IP t-PA和/或IP DNase进行胸膜感染,则将患者包括在内;如果接受IP t-PA或IP DNase进行胸管清除,则将患者排除。结果:共纳入197例IP t-PA和IP DNase,共30例患者。纳入患者的平均年龄为62岁,其中50%为女性。在纳入的30位患者中,有18位患者(60%)接受了IP t-PA和IP DNase治疗,有12位患者(40%)仅接受了IP t-PA。接受IP t-PA的中位剂量为4 mg(IQR 2-10),接受IP DNase的中位剂量为5 mg(IQR 5-5)。在给予IP t-PA或IP DNase之前,有77%的患者使用了全身性抗生素。据报道70%的患者胸腔积液引流得到改善。据报道,有7%的患者在服用IP t-PA或IP DNase期间胸腔疼痛加剧。结论:我们机构的大多数患者在尝试全身性治疗胸膜感染后均接受了IP t-PA和IP DNase治疗。施用IP t-PA和IP DNase可以改善引流性胸膜感染,对患者的伤害最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号